ArticlePloS one2013
Inhibition of type I insulin-like growth factor receptor signaling attenuates the development of breast cancer brain metastasis.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 34 citations in OpenAlex.
- A Phase 0 Trial of Ceritinib in Patients with Brain Metastases and Recurrent Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- Beyond the Walls of Troy: A Scoping Review on Pharmacological Strategies to Enhance Drug Delivery Across the Blood-Brain Barrier and Blood-Tumor Barrier.International journal of molecular sciences · 2025Article
- IGF1R activates FOXP3-β-catenin signaling to promote breast cancer development.Breast cancer research and treatment · 2025Article
- Targeting kinases that regulate programmed cell death: a new therapeutic strategy for breast cancer.Journal of translational medicine · 2025Review
- Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer.Molecular biomedicine · 2022Review
- Pharmacological Properties to Pharmacological Insight of Sesamin in Breast Cancer Treatment: A Literature-Based Review Study.International journal of breast cancer · 2022Review
- Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines.Cancer research · 2020Review
- Pericyte-secreted IGF2 promotes breast cancer brain metastasis formation.Molecular oncology · 2020Article
- GIPC-Regulated IGFBP-3 Promotes HSC Migration In Vitro and Portal Hypertension In Vivo Through a β1-Integrin Pathway.Cellular and molecular gastroenterology and hepatology · 2020Article
- Metastatic and triple-negative breast cancer: challenges and treatment options.Drug delivery and translational research · 2018Review
- Article
- Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives.Annals of oncology : official journal of the European Society for Medical Oncology · 2017Review
- The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer.Cancer metastasis reviews · 2016Review
- The insulin-like growth factor-I receptor (IGF-IR) in breast cancer: biology and treatment strategies.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- Changing molecular profile of brain metastases compared with matched breast primary cancers and impact on clinical outcomes.British journal of cancer · 2016Article
- Strategies to target drugs to gliomas and CNS metastases of solid tumors.Journal of neurology · 2016Review
- Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors.BMC cancer · 2015Article
- βIII-Tubulin Regulates Breast Cancer Metastases to the Brain.Molecular cancer therapeutics · 2015Article
- Review
- Epithelial-to-mesenchymal transition in breast cancer: a role for insulin-like growth factor I and insulin-like growth factor-binding protein 3?Breast cancer (Dove Medical Press) · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
Abstract
Brain metastasis is a common cause of mortality in cancer patients, yet potential therapeutic targets remain largely unknown. The type I insulin-like growth factor receptor (IGF-IR) is known to play a role in the progression of breast cancer and is currently being investigated in the clinical setting for various types of cancer. The present study demonstrates that IGF-IR is constitutively autophosphorylated in brain-seeking breast cancer sublines. Knockdown of IGF-IR results in a decrease of phospho-AKT and phospho-p70s6k, as well as decreased migration and invasion of MDA-MB-231Br brain-seeking cells. In addition, transient ablation of IGFBP3, which is overexpressed in brain-seeking cells, blocks IGF-IR activation. Using an in vivo experimental brain metastasis model, we show that IGF-IR knockdown brain-seeking cells have reduced potential to establish brain metastases. Finally, we demonstrate that the malignancy of brain-seeking cells is attenuated by pharmacological inhibition with picropodophyllin, an IGF-IR-specific tyrosine kinase inhibitor. Together, our data suggest that the IGF-IR is an important mediator of brain metastasis and its ablation delays the onset of brain metastases in our model system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.